India plans tariffs to counter US steel, aluminium duties
Tired of too many ads?
Remove Ads
Tired of too many ads?
Remove Ads
New Delhi: India on Wednesday proposed retaliatory tariffs against the US under the World Trade Organisation (WTO) norms over American tariffs on steel and aluminium in the name of safeguard measures "The safeguard measures would affect $7.6 billion imports into the United States of the relevant products originating in India, on which the duty collection would be $3.82 billion," India told the WTO.Last week, India proposed retaliatory tariffs against the US' auto duties.The proposed suspension of concessions or other obligations would take the form of an increase in tariffs on selected products originating in the US."Accordingly, India's proposed suspension of concessions would result in an equivalent amount of duty collected from products originating in the US," India said.In May, India had proposed to impose retaliatory duties on certain American products under the WTO to counter the American tariffs on steel and aluminium in the name of safeguard measures. New Delhi told the WTO that these measures would affect $7.6 billion imports into the US."This notification is made in connection with safeguard measures extended by the US on imports of aluminium, steel and derivative articles" India said Wednesday.The development assumes significance as India and the US are negotiating a trade agreement, the first tranche of which is to be concluded by September-October.On March 8, 2018, the US promulgated safeguard measures on certain steel and aluminium articles by imposing 25% and 10% ad valorem tariffs respectively on such products with effect from March 23, 2018. On February 10, 2025, it revised the safeguard measures on imports of steel and aluminium articles, effective from March 12.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
2 minutes ago
- Business Standard
Spain, UAE visit set to create over 14,000 jobs in state, says MP CM
Madhya Pradesh Chief Minister Mohan Yadav on late Sunday night said that his official visit to the UAE and Spain is set to create over 14,000 jobs in the state. Yadav stated that following the Madhya Pradesh Global Dialogue-2025, the state received investment proposals worth over Rs 11,119 crore. In a post on X, CM Yadav stated, "With the motto 'Make in India-Make in Madhya Pradesh,' investment proposals worth over Rs 11,119 crore have been received in all major sectors under the 'Madhya Pradesh Global Dialogue-2025' concluded in UAE and Spain. These will create more than 14,000 new employment opportunities in the state. After the visit to both nations, I reached Bhopal today and shared information with journalist friends." "In Madrid, Spain, the 'Invest in Madhya Pradesh - Business Forum' was held, where discussions took place with over 200 corporate and diplomatic representatives," he said. "Addressed over 500 expatriate entrepreneurs at the 'Friends of MP' conference held during the Dubai visit. Conducted one-to-one strategic meetings with heads of more than 30 international and national companies during the visit," he added. CM Yadav stated that, under the Madhya Pradesh Global Dialogue-2025, he signed MoUs and held productive talks with investors to promote the state's potential growth. In a post on X on Saturday, CM Yadav said, "Under the Madhya Pradesh Global Dialogue-2025, during the Spain visit, I engaged in discussions with entrepreneurs, investors, and businesspersons, signed MoUs, observed global agri-models like Mercabarna, and also met with the Indian diaspora. This visit will strengthen the vision of a developed Madhya Pradesh on the global stage." CM Yadav on Saturday said that his visit to Dubai and Spain is nearing its conclusion, highlighting the tour's focus on exploring opportunities for the state's progress and promoting employment, industries, and tourism. Speaking from Barcelona, CM Yadav said, "We have reached the last leg of our Dubai and Spain visit. As we had set the objective of our tour, we were to explore all the areas for the progress of our state with our Indians connected to Madhya Pradesh, especially everything that provides employment. We also went to the industries and restaurants to promote tourism. Wherever there are Indian restaurants, we visited them.
&w=3840&q=100)
Business Standard
2 minutes ago
- Business Standard
Rich or resilient? Market valuation debate heats up amid Q1FY26 results
The outlook for global equities in 2025-26 remains uncertain, with Anand Rathi noting that sentiment around Indian equities is even more cautious Sai Aravindh Mumbai Listen to This Article The long-drawn debate on India's stock valuation is back in focus as the market has recouped nearly 75 per cent of its losses. While benchmark indices hover near long-term averages, some analysts argue that current 'rich' valuations claims overlook broader macroeconomic signals. Going ahead, besides macro-economic strength, corporate earnings growth, analysts suggest, holds the key for the markets to sustain at the current levels and even move higher. Analysts at Anand Rathi recently downplayed concerns around rich market valuations, citing two key factors. First, this does not take into account the strong macroeconomic and robust corporate earnings growth.
Mint
2 minutes ago
- Mint
Recommended stocks to buy today, 21 July, by India's leading market experts
Indian stock market benchmarks—the Sensex and the Nifty 50—ended lower on Friday, 18 July, marking their third consecutive weekly decline. The Nifty 50 slipped below the key 25,000 level, signalling sustained pressure on the broader market. On the day, the Nifty fell 143 points (0.57%) to close at 24,968.40, while the Sensex dropped 502 points (0.61%) to settle at 81,757.73. Over the past three weeks, the Sensex has shed nearly 2,300 points, or close to 3%, with the Nifty 50 also down around 3% in the same period. Here are three midcap stocks to buy as recommended by Raja Venkatraman: METROBRAND (Cmp 1225.90) METROBRAND: Buy CMP and dips to ₹1200, stop ₹1180 target ₹1350-1400 Why it's recommended: Metro Brands has entered a long-term partnership with Clarks as its exclusive retail and digital partner in India and neighboring countries. The prices have dipped into the cloud support and formed a rounding pattern. The long body bullish candle seen on Friday augurs well for the prices. This has led to an improvement in the sentiment. With prices holding firm we can consider going long. Key metrics: P/E: 95.57, 52-week high: ₹1430.10, Volume: 67.07K. Technical analysis: Support at ₹1130, resistance at ₹1500. Risk factors: Macroeconomic and political risks , cyberattacks and weak same-store sales. Buy at: CMP and dips to ₹1200. Target price: ₹1350-1400 in 1 month. Stop loss: ₹1180. DALBHARAT (Cmp 2251.80) DALBHARAT: Buy CMP and dips to ₹2210, stop ₹2190 target ₹2450-2550 Why it's recommended: Dalmia Bharat Ltd. is a cement manufacturing company. The firm engages in the business of inter alia, manufacturing and selling of cement, and refractories and generating power. The stock has been consolidating at the TS & KS bands and forming rounding patterns and inching higher. Key metrics: P/E: 222.33, 52-week high: ₹2257.70 Volume: 580.40K Technical analysis: Support at ₹2100, resistance at ₹2700. Risk factors: Global economic slowdown, trade tensions, and specific challenges related to the power generation sector. Buy at: CMP and dips to ₹2210. Target price: ₹2450-2550 in 1 month. Stop loss: ₹2190. NATCOPHARMA (Cmp 1035.10) NATCOPHARMA: Buy at CMP and dips to ₹980, stop ₹950 target ₹1135-1165 Why it's recommended: The counter has undergone some ranging action as moving steadily higher forming a higher high higher low since mid-May 2025. On a recovery it faced a value area resistance that kept halting the upmove forming higher high and higher lows holding the TS & KS Bands for the past few days around 980 has been overcome. With steady volumes building up within the bands one can look for an encouraging upmove in the coming days. Key metrics: P/E: 10.02, 52-week high: ₹1638, Volume: 1.51M. Technical analysis: Support at ₹900, resistance at ₹1190. Risk factors: High Product Concentration, USFDA Warning letter and Patent disputes and litigation Buy at: above 670 and dips to ₹980 Target price: ₹1135-1165 in 1 month. Stop loss: ₹950. Stocks to trade today, recommended by Trade Brains Portal: Tata Communication Ltd Current price: ₹1,764 Target price: ₹2,085 in16-24 months Stop-loss: ₹1,600 Why it's recommended: Founded in 1986, Tata Communications Ltd., a part of the Tata Group, is a global digital ecosystem facilitator that supports the fast-expanding digital economy in over 190 countries and territories. Through a wide range of services, including next-generation connectivity, cloud and security solutions, collaboration tools, media services, IoT, and customer engagement platforms, the company drives digital transformation for businesses all over the world. Tata Communications links organizations to 80% of the top cloud providers globally, and it serves 300 of the Fortune 500 firms. Consolidated operating revenue in Q1 FY26 was ₹5,959.85 crore, up 6.5% YoY from ₹5,592.32 crore in Q1 FY25. For the first quarter of FY26, the company's profit after taxes was ₹190.14 crore. Over the past two years, the company has maintained its growth momentum, with digital revenues increasing 29.5%, from ₹4,500 crore in FY23 to ₹9,100 crore in FY25. In India and abroad, the business experienced strong year-over-year growth in the enterprise market segment. In FY25, international enterprise increased by up to 20% year over year, while Indian enterprise rose by 8.7% year over year. Regarding acquisitions, the business is putting cost-synergy initiatives into action. Although Switch and Kaleyra have been working on this for 24 and 18 months, respectively, they are both approaching the inflection point, and it is anticipated that the synergies will become apparent in the upcoming quarters. Also, the company board approved the Inter Group Share Purchase Agreement (SPA) for the purchase of Solutions Infini Technologies (India) Private Ltd (also known as "SI India") from Kaleyra S.P.A. for a total of ₹123.6 crore. The company is foraying into new segments like digital fabric tools and AI cloud. They already exist in very promising categories like CIS (Customer Interaction Suite), Secure Access Service Edge (SASE), and Unified Cloud Network (UCN). The need for sophisticated cybersecurity, scalable cloud infrastructure, and robust networks is rising significantly as a result of the industry's rapid adoption of AI. Tata Communications is in a strong position to take advantage of this chance by adding innovative solutions to its portfolio in important areas. Risk factors: The rivalry for Tata Communications is intensifying in a number of areas. System integrators are growing their managed service offerings, OEMs are venturing into the cybersecurity market, cloud providers are progressively branching out into telecom services, and specialized technology suppliers are going straight for business clients. At the same time, enterprise services are becoming more and more important to traditional telecom companies. The company may see pricing challenges and a drop in its margins if it can't keep its market leadership and effectively differentiate its services. Astral Ltd Current price: ₹1,507 Target price: ₹1,875 in 16-24 months Stop-loss: ₹1,320 Why it's recommended: Established in 1996, Astral Ltd has grown to become a market leader in the building materials industry, known for its high-quality and innovative products. As of FY25, the company has 26 manufacturing facilities and a combined production capacity of 5,49,126 (MTPA). They serve millions of consumers with excellence and dependability through a strong network of 3,610+ distributors and 2.5+ lakh dealers. The company's product line includes eight high-growth product categories that make pipes and fittings, water tanks, adhesives and sealants, bathware, specialty valves, construction chemicals, and infrastructure products. Additionally, it has entered the paint, faucet, and sanitaryware industries. By exporting to more than 31 countries, Astral is also growing its global presence and providing high-quality products. The company's revenue for FY25 was ₹5,832.4 crore, up 3.4% year over year from ₹5,641.4 crore in FY24. Ebitda increased 2.8% YoY to ₹987.2 crore from ₹960.3 crore in FY24, with the net profit of ₹519 crore. Paints & adhesives business revenue climbed 9.1% YoY to ₹1636.1 crore, while their Plumbing business revenue grew by 1.3% to ₹4196.3 crore YoY. In the last five years, their revenue has grown at a CAGR of 16.5%, Ebitda has grown by 10.48% while PBT grew by 7.15%. The company has invested about ₹1,000 crore in new plant expansions in Hyderabad, Guwahati, Bhubaneswar, and Kanpur during the past two years. In addition to expanding Dahej's capacity for more chemistries in the upcoming year, the company is starting a fully automated solvent cement plant, which is the pipe-joining chemical plant. With the acquisition of Al Aziz Plastics, the company looks forward to expanding its product portfolio in domestic and international markets. In the upcoming years, Astral hopes to achieve 15% to 20% paint revenue by concentrating on quality and innovation. Risk factors: Astral's main raw materials, which include UPVC, CPVC, PPR, and HDPE resins, are derived from crude oil by-products. The price of these raw materials is directly impacted by changes in the price of crude oil globally, which has an effect on Astral's production costs and profitability. Two stock recommendations by MarketSmith India for 21 July: Buy: Jubilant Pharmova Ltd (current price: ₹1,232) Why it's recommended:Strong financial growth and profitability, leadership in radiopharma and specialty pharma, improving debt metric. Key metrics: P/E: 39.23, 52-week high: ₹1,309.90, volume: ₹66.42 crore Technical analysis: Cup with handle pattern breakout with above average volume Risk factors: Regulatory and quality risks, segmental and operational volatility. Buy at: ₹1,232 Target price: ₹1,390 in two to three months Stop loss: ₹1,170 Buy: Moil (current price: ₹382) Why it's recommended: Market leadership in manganese ore, strong link to steel sector growth. Key metrics: P/E: 19.82, 52-week high: ₹ 588, volume: ₹ 45.51 crore Technical analysis: 50-DMA bounce Risk factors: High dependence on steel sector, commodity price volatility. Buy at: ₹382 Target price: ₹430 in two to three months Stop loss: ₹363 Top 3 stocks recommended by Ankush Bajaj for 21 July: Buy: SAIL Ltd — Current Price: ₹136.45 Why it's recommended: Despite the broader market sell-off, SAIL managed to close over 2% higher on Friday, showing strong relative strength. The stock has taken support at the 20-day moving average on the daily chart, and the daily RSI stands at 60, indicating bullish momentum. This resilience suggests that the uptrend may continue in the near term. Key metrics: Support taken at 20-DMA; strength seen despite weak market. Pattern: Bounce from moving average with strong candle formation. RSI: Daily RSI at 60 confirms upward momentum. Technical analysis: The chart indicates strong support and the potential for a move toward ₹145 in the short term. Risk factors: A breakdown below ₹132 would invalidate the setup and invite renewed selling. Buy at: ₹136.45 Target price: ₹145.00 Stop loss: ₹132.00 Buy: HDFC AMC — Current Price: ₹5,590.00 Why it's recommended: On the daily chart, HDFC AMC has formed a triangle breakout pattern, supported by a strong RSI reading of 74, indicating robust momentum. On lower timeframes, the stock is trading above all key moving averages, which further strengthens the bullish outlook. A continuation of this rally could lead to much higher levels. Key metrics: Triangle pattern breakout on daily chart with high RSI. Pattern: Bullish triangle breakout with volume support. RSI: Strong daily RSI at 74 signals momentum continuation. Technical analysis: The structure suggests an ongoing breakout with scope for further upside towards ₹5,680 and higher. Risk factors: A fall below ₹5,545 would negate the breakout and weaken the trend. Buy at: ₹5,590.00 Target price: ₹5,680.00 Stop loss: ₹5,545.00 Buy: Glenmark Pharma — Current Price: ₹2,225.50 Why it's recommended: Glenmark Pharma has formed abullish pennant pattern on the daily chart, indicating a continuation of its recent strong uptrend. The hourly RSI is trending higher at 59, showing that momentum is picking up again after recent profit booking. The stock made new highs recently, and this consolidation phase could lead to a fresh breakout toward lifetime highs. Key metrics: Bullish pennant breakout on the daily chart. Pattern: Pennant pattern with momentum re-emergence. RSI: Hourly RSI at 59 showing strength returning. Technical analysis: The price action suggests that the stock may be ready for another leg up towards ₹2,280, with potential to go even higher. Risk factors: A move below ₹2,194 would invalidate the bullish setup. Buy at: ₹2,225.50 Target price: ₹2,280.00 Stop loss: ₹2,194.00 Trade Brains Portal is a stock analysis platform. Its trade name is Dailyraven Technologies Pvt. Ltd, and its Sebi-registered research analyst registration number is INH000015729. Ankush Bajaj is a Sebi-registered research analyst. His registration number is INH000010441. Raja Venkatraman is the co-founder of NeoTrader. His Sebi-registered research analyst registration no. is INH000016223. MarketSmith India is a stock research platform and advisory service focused on the Indian stock market. Its trade name is William O'Neil India Pvt. Ltd, and its Sebi registration number is INH000015543. Investments in securities are subject to market risks. Read all the related documents carefully before investing. Registration granted by Sebi and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Disclaimer: The views and recommendations given in this article are those of individual analysts. These do not represent the views of Mint. We advise investors to check with certified experts before making any investment decisions.
